Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study

Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study

Background Heart failure mortality remains high despite recent progress in pharmacological treatment. AZD3427 is a selective long‐acting analog of relaxin, a vasodilatory hormone with antifibrotic effects. We assessed the safety, pharmacokinetics, and pharmacodynamics of AZD3427 in healthy volunteer...

Full description

Saved in:
Bibliographic Details
Main Authors: Kathleen Connolly, Richard George, Sami Omar, Elin Matsson, Magnus Åstrand, Magnus Althage, Daniel Pettersen, Esha Mohamed, Kelly Fang, Joao A. C. Lima, Mirjana Kujacic, Helena Ödesjö, Michelle Turton, Petra Johannesson, Anders Gabrielsen, Marcin Ufnal
Format: Article
Language:English
Published: Wiley 2024-08-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
AZD3427
HFmrEF
HFpEF
HFrEF
relaxin
RXFP1
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.034067
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.123.034067

Similar Items